Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL Meeting Abstract


Authors: Hallek, M.; Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Pagel, J. M.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I. W.; Ghia, P.; Eradat, H.; Erwin, T.; Lamanna, N.; Coiffier, B.; Pettitt, A. R.; O'Brien, S. M.; Cheson, B. D.; Ruppert, S.; Kronig, H.; Schuster, A.
Abstract Title: Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL
Meeting Title: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie
Journal Title: Oncology Research and Treatment
Volume: 37
Issue: Suppl.5
Meeting Dates: 2014 Oct 10-14
Meeting Location: Hamburg, Germany
ISSN: 2296-5270
Publisher: S. Karger AG  
Date Published: 2014-10-01
Start Page: 52
End Page: 53
Language: English
ACCESSION: WOS:000343816900120
PROVIDER: wos
PUBMED: 25301272
DOI: 10.1159/000368945
Notes: Meeting Abstract: P191 -- Annual Meeting of the German, Austrian and Swiss Societies of Hematology and Medical Oncology -- 5 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew D Zelenetz
    767 Zelenetz
Related MSK Work